Pulmobiotics SL
- Biotech or pharma, therapeutic R&D
Pulmobiotics: Engineering Living Medicines for Complex Lung Diseases
- Pulmobiotics is a Barcelona-based synthetic biology company pioneering the development of engineered live biotherapeutics for severe respiratory diseases with high unmet medical need.
- Founded in 2020, Pulmobiotics has secured €7 million in equity and non-dilutive funding to date. The company’s proprietary platform is built around a genetically engineered Mycoplasma pneumoniae chassis—uniquely adapted to colonize the lung and deliver therapeutic proteins directly at the site of disease.
- Our lead program, PB_LC, is an inhaled therapy designed for non-small cell lung cancer (NSCLC) patients who no longer respond to immunotherapy. PB_LC integrates multiple mechanisms of action and works locally in the lung, aiming to boost treatment efficacy while minimizing systemic toxicity—a common limitation of current cancer therapies.
- We are raising a €12.5 million Series A to advance PB_LC into first-in-human Phase I clinical trial.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}